NDAINTRAVENOUSPOWDER
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tigecycline is a broad-spectrum intravenous tetracycline-class antibiotic approved by the FDA in 2016 for treating complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. It works by inhibiting bacterial protein synthesis across a wide range of gram-positive, gram-negative, and anaerobic pathogens. The drug is administered as an intravenous powder formulation.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30/100), indicating stable sales but limited growth opportunity for expanding teams.
Mechanism of Action
Pharmacologic Class:
Tetracycline-class Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
Started Nov 2012
470 enrolled
Intra-abdominal Infection
Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
Started Mar 2012
12 enrolled
Obesity
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects
Started Aug 2011
0Skin DiseasesInfection
Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
Started Jul 2011
10 enrolled
DiarrheaClostridium Difficile
Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia
Started Mar 2011
27 enrolled
Acute Myeloid Leukemia
Worked on TIGECYCLINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.